Kornimate/medical-research-clean huggingface dataset:
web-based insomnia treatment for adolescent and young adult cancer survivors

Conditions: Insomnia

Summary: this research study is evaluating a six-session online program designed to help insomnia (difficulty falling or staying asleep) in adolescent and young adult cancer survivors.

the purpose of this study is to learn whether an adapted version of shuti (sleep healthy using the internet), a six-session online program which has been found to be effective in other groups of people, will be useful in treating insomnia in adolescent and young adult cancer survivors.

Eligibility criteria:
inclusion criteria: * 14-25 years of age * history of a cancer diagnosis * no active cancer therapy (excluding chemoprevention) in the past three months, and no cancer therapy currently planned in the next 6 months * no surgery planned in the next 6 months * significant insomnia as evidenced by an insomnia severity index score ≥12 * able to read and write in english * has internet access at home * motivated and able to follow the demands of the shuti program, to keep sleep records, complete self-report symptom reports and make changes in their sleep schedule, including restricting their sleep exclusion criteria: * prior attempt(s) to treat insomnia using cognitive-behavioral treatment for insomnia * history of bipolar disorder diagnosis * history of a seizure disorder diagnosis or have experienced a seizure in the past 12 months * intention to adjust (decrease or increase) use of sedative, hypnotic, or over-the-counter (e.g., benadryl, unisom) medications that can affect sleep during the study period * diagnosed, untreated sleep apnea or sleep apnea suspected by a physician but which has not been unevaluated, or other sleep disorder * employment that involves irregular sleep patterns, such as shift-work or frequent long-distance travel that involves adjusting to different time zones, or employment in a position that could impact public safety (such as operating heavy machinery) * refusal to modify or reduce excessive alcohol use that is likely to interfere with an individual's sleep

Keywords: insomnia
meu-cinn for gastric mucosal health in adults with functional dyspepsia

Conditions: Functioanl Dyspepsia

Summary: this clinical trial aims to determine whether meu-cinn promotes gastric mucosal health in adults with functional dyspepsia and to assess its safety. the main questions are: * does meu-cinn promote gastric mucosal health in participants? * what side effects occur when participants take meu-cinn?

researchers will compare meu-cinn to placebo to evaluate their effectiveness in promoting gastric mucosal health. participants will: * take meu-cinn or a placebo daily for 8 weeks. * visit the clinic at 1, 2, 4, and 8 weeks for checkups and tests.

Eligibility criteria:
inclusion criteria: * rome iv-based functional dyspepsia- exclusion criteria: * patients with gastrointestinal symptoms requiring immediate drug treatment. * individuals with a history of hypersecretory gastric disorders like zollinger-ellison syndrome. * individuals who received helicobacter pylori eradication therapy within 4 weeks prior to the trial. * individuals who have taken nonsteroidal anti-inflammatory drugs, steroids, antibiotics, aspirin, antithrombotic agents, or acid suppressants within the last month. * individuals with a history of upper gastrointestinal surgery, stricture, bleeding, or procedures like esophageal dilation or mucosal resection within the last year. * individuals with gastric ulcers (active or healing), duodenal ulcers (active or healing), reflux esophagitis (la grade a or higher), or malignant tumors identified within the last 6 months through endoscopy. * patients with uncontrolled hypertension (resting bp ≥160/100 mmhg). * patients with uncontrolled diabetes (fasting glucose ≥160 mg/dl). * individuals with creatinine levels ≥ 2 times the upper limit of normal at the research institution. * individuals with aspartate aminotransferase or alanine aminotransferase levels ≥ 2 times the upper limit of normal at the research institution. * alcohol abusers. * individuals taking medications for psychiatric disorders (except those taking intermittent medication for sleep disorders). * pregnant or breastfeeding women or those planning to become pregnant during the clinical trial period. * individuals with allergies to any components of the study foods. * individuals who participated in or plan to participate in another drug clinical trial within the last month. * individuals deemed unsuitable for the study by the investigator for other reasons.
prognosis of mettl-14 in endometrial carcinoma

Conditions: Endometrial Cancer; Endometrial Adenocarcinoma

Summary: 1. to evaluate immunohistochemical expression of mettl14 in type1 endometrial carcinoma. 2. to evaluate the correlation between mettl14 expression and clinicopathological parameters of patients with type 1endometrial carcinoma such as tumor grade, lymhovascular invasion, age of pateints, tumor stage, presence of myometrial invasion and presence of cervical stroma affection. 3. to assess correlation of mettl-14 expression with disease free survival and overall survival.

endometrial cancer(ec) is the second most common gynecologic cancer worldwide(1). in egypt its incidence rate has increased in recent years, reaching 4.1 per 100,000 women(2). the most common histological subtype is endometrioid adenocarcinoma(3). endometrial carcinoma can be divided into:type i and type ii tumors. the incidence of type i is 60-80% and that of type ii is 20%(4). n6-methyladenosine (m6a)is the most abundant rna modification in mammalian mrna and has a crucial role in the occurrence and development of various diseases, particularly malignant tumors(3). many factors were found to affect the prognosis of endometrial carcinoma, one of these factors is m6a rna methylation(5). this modification is dynamic and reversible, and it is catalyzed by three main types of regulators(3). it has been reported that m6a methylation was performed via methyltransferase complex regulators composed of "writer," "eraser," and "reader"(6). methyltransferase like 14 (mettl14), a member of "writer", acts to regulate the occurrence of various cancers(7). in most tumors mettl14 acts as an antioncogene, regulating the rna of genes that help the cell detect and repair dna damage, acting as a protective mechanism against cancer. reducing m6a mrna may be due to mettl14 mutation. reducing m6a mrna levels in endometrial cancer cells could enhance cell proliferation and tumorigenicity in vitro and in vivo(8).the role of mettl14 as a risk factor in prognosis of endometrial carcinoma is still unknown.

Eligibility criteria:
inclusion criteria: * cases of type1endometrial carcinoma with: 1. hystrectomy operation 2. available full clinical data about patient (age, complaint, findings in clinical examination). 3. full data about previous biopsy and radiology. 4. full data about patient survival, disease progression and history of chemotherapy for three years. exclusion criteria: * 1. any case of type 1 endometrial carcinoma with missing clinical, radiologic or follow up data. 2. cases with no available h\&e stained slides or formalin fixed paraffin embedded block. 3.d\&c.
role of interleukin (il)-1 in postprandial fatigue - the chäschüechli 2 study

Conditions: Adiposity

Summary: role of il-1 in postprandial fatigue - the chäschüechli 2 study it is a randomized, single dose, placebo-controlled, double blind, cross-over, proof-of-concept study. 16 healthy young men will be included in this study. the objective of this study is to evaluate if severity of postprandial fatigue is driven by il-1. since fatigue is associated with increased cytokine levels, and since fatigue in chronic inflammatory settings, such as type 2 diabetes, can be reduced by inhibition of il-1β, postprandial fatigue might also respond to anti-inflammatory intervention with il-1 inhibition. the aim of the study is to investigate whether postprandial fatigue is, at least in part, driven by the il-1 system.


Eligibility criteria:
inclusion criteria: male subjects * non-smoking * apparently healthy * bmi \>18 and ≤28 kg/m2 or bmi \>30 and ≤35 kg/m2 * age 20-65 years * subject is usually eating breakfast and lunch * willingness to use contraceptive measures adequate to prevent the subject's partner from becoming pregnant during the study. adequate contraceptive measures include hormonal methods used for two or more cycles prior to screening (e.g., oral contraceptive pills, contraceptive patch, or contraceptive vaginal ring), double barrier methods (e.g., contraceptive sponge, diaphragm used in conjunction with contraceptive foam or jelly, and condom used in conjunction with contraceptive foam or jelly), intrauterine methods (iud) and sterilization (e.g., tubal ligation or a monogamous relationship with a vasectomized partner). * owner of a smartphone so they will be able to download and use the sleeping app, sleep cycle, prior to the study days. exclusion criteria: subjects will be excluded from the study if they meet any of the following criteria: * night shift workers * subjects suffering from sleep disturbances * clinical signs of infection in the week before inclusion or history of infection during the last 2 months (crp \>5mg/l) * impaired fasting glucose (fasting plasma glucose \>5.5mmol/l) * hematologic disease (leukocyte count \< 1.5x109/l, hemoglobin \<11 g/dl, platelets \<100 x 103/ul) * kidney disease (creatinine \> 1.5 mg/dl)) * liver disease (transaminases \>2x upper normal range) * heart disease * pulmonary disease * inflammatory disease * history of carcinoma * history of tuberculosis * alcohol consumption \>40g/d * smoking * known allergy towards kineret * known allergy to ingredients of the test meal * current treatment with any drug in the week before inclusion, including vitamin supplementation (especially vitamin c and e) * use of any investigational drug within 30 days prior to enrolment or within 5 half-lives of the investigational drug, whichever is longer * subject refusing or unable to give written informed consent
optimization of therapeutic human serum albumin infusion in selected critically ill patients

Conditions: Shock; Systemic Inflammatory Response Syndrome (SIRS); Hypoalbuminaemia

Summary: primary purpose : mortality at day 28 secondary purposes : * daily sofa (sequential organ failure assessment) score lessening within intensive care unit (icu) * duration of increasing doses of norepinephrine infusion to maintain target mean arterial pressure * number of care-related infections within icu

according to currently available literature on therapeutic albumin infusion in critically ill patients, there is room for new approaches to delineate an optimal use of this expansive treatment. indeed, many authors suggest that the present clinical use of albumin is questionable in critically ill patients as far as changes in morbidity or mortality are concerned and with regards to cost-effectiveness. it has been reported that protein misfolding and aggregation are a hallmark of several inflammatory diseases. in vitro studies show that very small amounts of albumin are able to restore the physiologic activities of endogenous circulating proteins that had been aggregated in multimeric form during oxidative stress. recently, the investigators have reported that in vitro albumin restores antimicrobial and anti-inflammatory effects of some chromogranin a-derived peptides. the investigators therefore search to test in vivo, in critically ill patients with severe systemic inflammation requiring norepinephrine infusion, whether therapeutic albumin infused at a low and continuous dosage may modify mortality (primary purpose) and morbidity (secondary purposes) in comparison with intermittent high dosage albumin infusion.

Eligibility criteria:
inclusion criteria: * circulatory failure requiring norepinephrine support (any dose) * hospitalization within an intensive care unit * sirs * low plasma albumin (\< 20g/l) * consent to study exclusion criteria: * absence of circulatory failure * absence of sirs * chronic low albumin concentration * absence of consent to study * inability to tolerate human serum albumin * patients under guardianship or curators * women pregnant

Keywords: acute circulatory failure requiring norepinephrine sirs albumin, therapeutic
comparison of brivanib and best supportive care to placebo for treatment of liver cancer for those subjects who have failed sorafenib treatment

Conditions: Liver Cancer

Summary: the purpose of this study is to determine if brivanib is an effective treatment for liver cancer in patients who have failed or could not take sorafenib


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com. inclusion criteria: * histologic or cytologic confirmed diagnosis of hcc * advanced disease defined as (i) disease not eligible for surgical or loco-regional therapy or (ii) disease progressive after surgical or loco-regional therapy * patient has failed ≥ 14 days of sorafenib treatment * cirrhotic status of child-pugh class a or b with a score of 7 * eastern cooperative oncology group (ecog) performance status 0, 1, 2 * subjects who have a life expectancy of at least 8 weeks * adequate hematologic, hepatic, and renal function exclusion criteria: * women of childbearing potential (wocbp) who are unwilling or unable to use an acceptable method to avoid pregnancy * previous or concurrent cancer that is distinct in primary site * history of active cardiac disease * thrombotic or embolic events within the past 6 months * any other hemorrhage/bleeding event \> common terminology criteria for adverse events (ctcae) grade 3 within 4 weeks * inability to swallow tablets or untreated malabsorption syndrome * history of human immunodeficiency virus (hiv) infection * prior use of systemic investigational agents for hcc (except for sorafenib)
unity total knee replacement using two different surgical techniques

Conditions: Arthritis of the Knee

Summary: this study will compare two different surgical methods used in total knee replacement with the unity total knee replacement system. the study will evaluate these two methods based on patients' ability to perform various tasks prior to surgery and at 4 time points during the first 12 months after surgery.

this study will be conducted at a single centre. the study has two treatment groups. one group of 50 knees (approximately 50 subjects) will have a surgical method that uses mechanical alignment (alignment based on how the leg and knee joint move) to determine the proper position of the knee replacement device. the other group of 50 knees (approximately 50 subjects) will have a surgical method that uses anatomical alignment (alignment based on how the anatomy/structure of the leg and knee joint) determine the proper position of the knee replacement device. subjects will be randomly assigned to one of the two groups. clinical and functional tests will be conducted pre-operatively and at 6 weeks, 3 months, 6 months and 12 months to determine overall knee function. in addition, a ct scan will be completed pre-operatively and at 6 weeks to assess changes in alignment.

Eligibility criteria:
inclusion criteria: * the patient must be listed for a primary total knee replacement using the corin unity total knee replacement system, according to the product 'instructions for use' * the patient must give signed informed consent to participate in the study * the patient must be able to understand all that is expected of them and be able to comply with the study protocol * male and female patients who are skeletally mature exclusion criteria: * any patient with a total knee replacement not implanted with a corin unity total knee replacement * any patient with a revision total knee replacement or conversion of a unicondylar replacement to a total knee replacement on the operative knee * any patient with fixed flexion contracture greater than 20 degrees * any patient with varus/valgus deformity greater than 15 degrees * any case not described in the inclusion criteria * any patient who cannot or will not provide signed informed consent for participation in the study * any patient whose prospects for a recovery to independent mobility would be compromised by known co-existent, medical problems * any patient with a known sensitivity to device material * any patient who is pregnant * any patient currently a prisoner * any patient known to be a drug or alcohol abuser, or have a psychological disorder that could affect follow-up care or treatment outcomes * any patient currently involved in any personal injury litigation, medical-legal or worker's compensations claims * any patient unable to read and understand english

Keywords: arthroplasty, replacement, knee/methods knee joint/physiopathology knee joint/radiography knee joint/surgery knee prosthesis outcome assessment (health care) female male adult
registry of seraph®-100 microbind® affinity blood filter for covid-19 under eua

Conditions: COVID-19; SARS-CoV 2

Summary: severe acute respiratory syndrome coronavirus-2 (sars-cov-2) has caused a global pandemic and is associated with significant morbidity and mortality. the mortality rate for covid-19 patients admitted to an intensive care unit (icu) who require mechanical intubation is approximately 75%. while the pathophysiology of severe covid-19 has yet to be fully understood, it is possible that a combination of high viral loads and an overactive dysregulated inflammatory response may contribute. therefore, the clearance of sars-cov-2 virus and cytokines could provide a more opportunistic environment for the innate immune system to clear the virus and establish lasting immunity. the seraph®-100 microbind® affinity blood filter (seraph®-100) is an extracorporeal broad-spectrum sorbent hemoperfusion filter for removing virus and cytokines from the blood. the fda authorized an emergency use authorization (eua) for treatment of severe covid-19 with the seraph®-100. as part of the eua, this registry study will collect de-identified data to assess safety and efficacy on the use of seraph®-100 microbind® affinity blood filter in the treatment of covid-19 patients.


Eligibility criteria:
inclusion criteria: * confirmed covid-19 infection * confirmed or imminent respiratory failure * at least one of the following conditions 1. early acute lung injury (ali) or early acute respiratory distress syndrome (ards) 2. severe disease, defined as: * dyspnea, * respiratory frequency ≥ 30 bpm, * blood oxygen saturation ≤ 93%, * partial pressure of arterial oxygen to fraction of inspired oxygen ratio \< 300, and/or * lung infiltrates \> 50% within 24 to 48 hours 3. life-threatening disease, defined as: * respiratory failure, * septic shock, and/or * multiple organ dysfunction or failure exclusion criteria: * no exclusion
maternal serum stathmin-1 levels in preeclampsia

Conditions: Pre-Eclampsia

Summary: this study investigates maternal serum stathmin-1 (stmn-1) levels in pregnancies complicated by preeclampsia and severe preeclampsia, compared to healthy pregnancies. the aim is to explore potential differences in stmn-1 levels among these groups to better understand its role in preeclampsia pathophysiology. maternal serum stmn-1 levels will be measured between 32-34 weeks of gestation, and patients will be monitored until delivery to assess whether they develop preeclampsia or severe preeclampsia.


Eligibility criteria:
inclusion criteria: * clinical diagnosis of preeclampsia: defined by new-onset hypertension (systolic blood pressure ≥140 mmhg and/or diastolic blood pressure ≥90 mmhg) after 20 weeks of gestation, with or without proteinuria. * clinical diagnosis of severe preeclampsia: defined by criteria such as severe hypertension (systolic bp ≥160 mmhg or diastolic bp ≥110 mmhg), organ dysfunction (renal insufficiency, liver involvement, neurological complications), thrombocytopenia, pulmonary edema, or fetal growth restriction. * control group: healthy pregnancies without preeclampsia exclusion criteria: * multiple pregnancies * pregestational diabetes * chronic hypertension * systemic diseases (chronic kidney disease, autoimmune diseases) * fetal anomalies * premature rupture of membranes
a randomized, double-blind study of the effects of fenretinide administered in subjects with obesity

Conditions: Obesity; Insulin Resistance

Summary: many metabolic complications of obesity are a consequence of abnormal responses of the liver, muscle, and fat to insulin actions. fenretinide may improve the effects of insulin, preventing metabolic complications.


Eligibility criteria:
inclusion criteria: * bmi \>30 exclusion criteria: * diabetes requiring medication * poorly controlled co-morbidities

Keywords: obesity insulin resistance
phase 2 study of gemcitabine and docetaxel combination chemotherapy in patients with carcinoma of unknown primary

Conditions: Carcinoma of Unknown Primary

Summary: it's a phase 2, single arm study of gemcitabine an docetaxel combination in patients with carcinoma of unknown primary.


Eligibility criteria:
inclusion criteria: * 1. age\>=20 2. pathologically confirmed patients with carcinoma of unknown primary 3. unfavorable type of cup 4. ecog ps 0-2 5. more than 1 evaluable lesion 6. life expectancy \> 12 weeks 7. no prior history of chemotherapy 8. more than 2 weeks after surgery or radiotherapy 9. proper organ function 10. written informed consent exclusion criteria: * 1. favorable group cup * squamous cell carcinoma in the cervical or inguinal ln only women with axillary ln metastasis only women with peritoneal carcinomatosis only well-differentiated neuroendocrine tumors poorly-differentiated tumors with midline tumor or elevated human hcg/afp men with adenocarcinoma and elevated psa 2. severe, unstable heart disease 3. uncontrolled systemic disease (dm, htn, hypothyroidism, infection...) 4. pregnant or feeding women 5. current cns tumor (except total removal or wbrt/gks done)